title: Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage.
abstract: Dyslipidemia has been proven to play an important role in the occurrence and development of the ischemic stroke and lipid-lowering therapy could significantly decrease the risk of the ischemic stroke. However, the association between lipid levels, lipid-lowering therapy and the risk of intracerebral hemorrhage (ICH) is not clear. Studies have shown that low serum levels of total cholesterol might be associated with increasing risk of ICH, whereas the SPARCL study, a large prospective, randomized, placebo-controlled trial, demonstrated an increased risk of hemorrhagic stroke during high-dose statin therapy among the patients with previous stroke. The relationship between lipid-lowering therapy and ICH has become a hot topic in the recent years. We searched PubMed for articles published in English to review the existing evidence on the association of lipid levels, statin therapy and risk of ICH as well as the underlying mechanisms in order to provide practical recommendations for clinical decision-making and a foundation for further researches.
authors.affiliation: Department of Cardiology, The Second Xiangya Hospital, Central South University, #139 Middle Renmin Road, Changsha, Hunan, 410011, PR China.|The Eight-Year Clinical Medicine of Grade 2012, Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, PR China.
authors.forename: Yingxu
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Department of Cardiology, The Second Xiangya Hospital, Central South University, #139 Middle Renmin Road, Changsha, Hunan, 410011, PR China.|The Eight-Year Clinical Medicine of Grade 2012, Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, PR China.
authors.forename: Zhaokai
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Cardiology, The Second Xiangya Hospital, Central South University, #139 Middle Renmin Road, Changsha, Hunan, 410011, PR China.|The Eight-Year Clinical Medicine of Grade 2012, Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, PR China.
authors.forename: Liang
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Cardiology, The Second Xiangya Hospital, Central South University, #139 Middle Renmin Road, Changsha, Hunan, 410011, PR China. lixp@medmail.com.cn.
authors.forename: Xiangping
authors.initials: X
authors.lastname: Li
mesh_terms: D000818:Animals; D002543:Cerebral Hemorrhage / Q000453:epidemiology* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents